In addition, the degree of LDL-C and ApoB lowering achieved with both compounds was less than that observed with evinacumab in patients with severe hypertriglyceridemia or mixed dyslipidemia despite dramatic reductions in circulating ANGPTL3 levels3,5,34. The gene discussed is ANGPTL3; the disease is metabolic syndrome.